destiny-gastric03: trastuzumab deruxtecan in her2-overexpressing gastric cancer
Published 3 years ago • 893 plays • Length 4:41Download video MP4
Download video MP3
Similar videos
-
1:34
destiny-gastric03: t-dxd in her2 and her2-low gastric cancer
-
1:58
destiny-gastric02: t-dxd as a second-line treatment for her2-positive gastric cancer
-
1:43
gasther2: trastuzumab for advanced gastric cancer
-
2:40
destiny-gastric02: 2l t-dxd in her2 gastric cancers
-
3:25
considerations for molecular testing for her2 gastric cancer
-
3:12
advances in her2-targeted therapies for gastric cancer
-
3:02
updates from destiny-gastric 01
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
2:58
updated analysis of destiny-gastric02: t-dxd in her2 gej cancer who progressed with trastuzumab
-
6:45
trastuzumab deruxtecan for patients w/ her2-positive advanced gastric or ge junction adenocarcinoma
-
1:04
panthera: pembrolizumab, trastuzumab, and chemotherapy in her2 advanced gastric cancer
-
8:01
innovation: chemotherapy with trastuzumab and pertuzumab in her2 gastric cancer
-
1:15
evaluating trastuzumab deruxtecan in earlier lines of breast cancer therapy
-
2:27
destiny-breast03: practice-changing results from esmo 2021
-
11:32
final results from destiny-crc01: t-dxd in her2-expressing mcrc
-
2:37
remarkable data: trastuzumab deruxtecan for her2 bc
-
4:39
latest news in gastric cancer from asco gi
-
1:11
32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
-
0:54
perioperative pembrolizumab for stomach cancer treatment